Joseph Kenny, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1125 W Jefferson St, Franklin, IN 46131 Phone: 317-472-1148 |
Mr. Niall Richard Atkinson, FNP Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 198 E Jefferson St, Franklin, IN 46131 Phone: 317-736-7211 Fax: 317-736-6742 |
James Brantly, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1125 W Jefferson St, Franklin, IN 46131 Phone: 317-472-1148 |
Pamela Peak, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3250 W 100 S, Franklin, IN 46131 Phone: 317-722-6889 |
News Archive
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that data and study design features on PV-10 for metastatic melanoma were presented at the 2011 International Melanoma Congress on November 12, 2011, during the 5th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres meeting, in Tampa, Florida.
Columbia University School of Nursing is the only site in New York State, and one of only 30 international sites selected to participate in a clinical trial to treat Acquired Female Orgasmic Disorder.
According to a new study children born to mothers who have had any kind of fever during pregnancy are at a slightly higher risk of developing and autism spectrum disorder (ASD).
A group of researchers at the University of São Paulo's Engineering School (POLI-USP) in Brazil have developed a mechanical ventilator that costs only approximately 7% as much as a conventional ventilator.
Living Cell Technologies Limited, a company pioneering the development of a cell implant to treat diabetes, has obtained approval to commence a Phase II DIABECELL clinical trial in Buenos Aires, Argentina, DIABECELL's third jurisdiction to date which has approved human trials. Up to eight adult patients with Type 1 diabetes, including those with unstable diabetes and severe hypoglycaemia, will each receive two implants of DIABECELL, three months apart with a dose seeking component. The trial is expected to begin in the second half of this year.
› Verified 5 days ago